Why the study?
Hypertension is prevalent in chronic kidney disease and drives adverse outcomes, but definitive evidence for blood pressure targets and precise drug combinations is lacking, leading older antihypertensive classes to potentially be overlooked.
This review highlights the need to re-evaluate the role of older antihypertensive classes, such as thiazide diuretics, in the management of hypertension in chronic kidney disease.
Hypertension is both a cause and consequence of chronic kidney disease (CKD). As such, the prevalence of hypertension is high among CKD patients and the incidence increases as their kidney disease progresses. Given the high risk of mortality, morbidity and risk of progression to end-stage renal failure, blood pressure management remains a key focus in managing CKD patients. However, without strong definitive evidence for blood pressure targets, or clear data to support the precise combination of antihypertensive medications, practice variance increases as the number of drugs available to treat hypertension increases and older drug classes may be overlooked.
No takes yet. Share an insight, caveat, or question.
Haroon et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: